Indivior outlines 30% adjusted EBITDA growth target for 2026 with new $400M share repurchase program

Q4 2025 Management View CEO Joseph Ciaffoni stated that 2025 was a transition year, highlighting the successful completion of ...

Indivior PLC Q4 2025 Earnings Call Summary

Attributed 2025 performance to improved commercial execution and record SUBLOCADE net revenue of $856 million, a 13% year-over-year increase. Simplified the organizational structure to establish a ...

Indivior (INDV) Q4 2025 Earnings Call Transcript

Thanks, Jason, good morning and thank you for joining us on today's call to review our fourth quarter and full year 2025 results. Last July, we rolled out the Indivior Action Agenda to maximize the ...

Indivior Reports Fourth Quarter and Full-Year 2025 Financial Results

Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net ...
Business Insider

Indivior Announces New Drug Submission to Health Canada for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Moderate to Severe Opioid Use Disorder

A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". Health Canada Grants Priority Review Designation for SUBLOCADE™ SLOUGH, ...

Indivior earnings ahead: Investors eye SUBLOCADE growth story

Indivior PLC is set to report fourth-quarter and full-year 2025 results before the market opens Thursday, February 26, as Wall Street looks for evidence the addiction-treatment specialist can deliver ...
Seeking Alpha

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two approaches ...
Capitalbolsa

FDA Approves SUBLOCADE™ (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder

SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered ...
Nasdaq

SUBLOCADE® Long-Term Safety Data Published in Journal of Clinical Psychopharmacology

SLOUGH, England and RICHMOND, Va., April 16, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release) ...

Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript

Indivior Pharmaceuticals, Inc. ( INDV) Q4 2025 Earnings Call February 26, 2026 8:00 AM EST Good morning, everyone. I am joined today by Joe Ciaffoni, Chief Executive Officer; Pat Barry, Chief ...